InteRNA is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation platform and enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. With this approach, we address the high need for novel therapeutics with improved efficacy and less prone to drug-acquired resistance that will benefit cancer patients.
In 2009, InteRNA moved to its own offices and laboratories at the Utrecht Science Park near the Hubrecht Institute, Utrecht Medical Center and Utrecht University.
InteRNA has its statutory seat in Nijmegen (NL).
InteRNA Technologies aspires to improve cancer therapy effectiveness through innovative, intelligent miRNA-based therapeutics.